Edgewise Therapeutics, Inc. (EWTX) Stock Score, Valuation & Financial Research

Edgewise Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for EWTX

Edgewise Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 40.60. These figures are a research snapshot, not a buy or sell recommendation.

What Edgewise Therapeutics, Inc. does

Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Edgewise Therapeutics is a clinical-stage biopharmaceutical company that generates no product revenue. It funds its research and development operations primarily through the issuance of equity securities, including private placements and public offerings, and through strategic collaborations.

Products and services

  • The company is developing a pipeline of precision medicines for rare neuromuscular and cardiac diseases, including sevasemten for muscular dystrophy and other cardiovascular candidates.

Customer types

Patients with rare neuromuscular and cardiac diseases.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on third-party contract organizations for clinical trial management, data collection, and the manufacturing of drug candidates; specific supplier names are not disclosed. Source

Business relationships and partnerships

  • Servier — A definitive agreement under which Servier acquired sevasemten and the company's muscular dystrophy business for upfront cash and potential milestone payments. Source

Competitors and product-market comparisons

  • Biopharmaceutical companies — The company competes with various biopharmaceutical companies developing therapies for neuromuscular and cardiovascular diseases, though specific competitors are not named in the filing. Source

Business strengths to evaluate

  • Proprietary muscle-focused drug discovery platform Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on clinical trial success and regulatory approval Source

Sources: Company research source · Servier

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

EWTX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 40.60
Market capitalization:
4.37B (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -197.22M
Free cash flow:
USD -144.07M
Cash:
USD 72.32M
Total debt:
USD 3.59M
EPS:
USD -1.85

What stands out

  • Free cash flow is USD -144.07M, negative for the stored period.
  • The balance sheet shows USD 72.32M of cash versus USD 3.59M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 68.73M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for EWTX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can EWTX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is EWTX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for EWTX to reach sustainable profitability?
  • What does the current missing revenue history warning mean for the reliability or interpretation of EWTX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research EWTX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.